Spero Therapeutics, Inc.
SPRO- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001701108
Insider trades, last 90 days
None
- No open-market purchases or sales were filed in the last 90 days.
13F holders, Q2 2026
59
- +9 vs. Q1 2026
- Total value $47.53M
Superinvestors holding SPRO
0
- None of the superinvestors held SPRO at the end of Q2 2026.
Price chart
Latest insider trades
View all: Latest insider tradesOpen-market purchases and sales by SPRO insiders, newest first.
| Filed (ET) | Trade date | Insider | Transaction | Shares | Avg price | Value | Shares after | Holding change | Filing |
|---|---|---|---|---|---|---|---|---|---|
| May 6, 2026 | May 4, 2026 | Rajavelu EstherSee Remarks | SSaleCommon Stock | −25.24K | $2.51 | −$63.35K | 986.85K | −2.5% | SEC |
| Feb 9, 2026 | Feb 6, 2026 | Rajavelu EstherSee Remarks | SSaleCommon Stock | −87.92K | $2.36 | −$207.48K | 1.01M | −8.0% | SEC |
| Feb 9, 2026 | Feb 6, 2026 | Keutzer TimothyChief Operating Officer | SSaleCommon Stock | −18.65K | $2.36 | −$44.02K | 742.51K | −2.5% | SEC |
| Feb 5, 2026 | Feb 2 – Feb 4, 2026 | Keutzer TimothyChief Operating Officer | SSaleCommon Stock | −46.59K | $2.1718 | −$101.17K | 761.16K | −5.8% | SEC |
| Feb 4, 2026 | Feb 2, 2026 | Rajavelu EstherSee Remarks | SSaleCommon Stock | −18.44K | $2.20 | −$40.57K | 1.1M | −1.6% | SEC |
Top 5 13F holders, Q2 2026
View all: Top 5 13F holders, Q2 2026The largest institutional positions in SPRO at the end of Q2 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| GSK plc | 9,190,606 | $20.31M | 3.37% | 00.0% | Unchanged |
| Pfizer Inc | 2,362,348 | $5.34M | 3.13% | 00.0% | Unchanged |
| VANGUARD CAPITAL MANAGEMENT LLC | 2,036,226 | $4.5M | 0.00% | +236,346+13.1% | Added |
| RENAISSANCE TECHNOLOGIES LLC | 947,904 | $2.09M | 0.00% | −241,331−20.3% | Reduced |
| Alphabet Inc. | 889,979 | $1.97M | 0.00% | 00.0% | Unchanged |